CDK4 and breast carcinoma: Therefore, a low-risk CINSARC signature could identify Luminal B breast cancers with both relatively favorable outcome and relative resistance to chemotherapy, but with sensitivity to endocrine therapy and CDK4/6 inhibitors, making this combination an attractive alternative to evaluate in this population.